Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
Cingulate Inc. (CING), a Delaware corporation, filed this Current Report on Form 8-K on June 16, 2026. The company is an emerging growth company with its principal executive offices in Kansas City, KS. Its common stock and warrants trade on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a regulatory disclosure regarding intellectual property and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the issuance of U.S. Patent No. 12,653,791 by the United States Patent and Trademark Office (USPTO). This patent covers key aspects of the formulation and method of use for the company's candidate therapy, CTx-1301. The patent protection extends through December 2042. The company had previously announced a Notice of Allowance for this patent.
Guidance, Outlook, and Risks
The filing does not include updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure that the press release information is not deemed "filed" under Section 18 of the Exchange Act. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the patent scope.
- Confirm the status of CTx-1301 clinical trials and development timeline in recent periodic reports (10-K/10-Q).
- Review the company's cash position and burn rate in the most recent quarterly filing, as this 8-K contains no liquidity data.
- Check for any pending litigation or challenges regarding the newly issued patent.